Document Detail


Structure of COX-1 and COX-2 enzymes and their interaction with inhibitors.
MedLine Citation:
PMID:  12973429     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Cyclooxygenase (COX) is the central enzyme in the biosynthetic pathway to prostaglandins (PGs) from arachidonic acid (AA). This protein was purified more than 20 years ago and cloned in 1988. A few years later another protein with COX activity was identified and called COX-2. Although the isoforms of COX are derived from different genes of different size and give rise to distinct mRNA sequences, the proteins are highly homologous in sequence and in three-dimensional structure. They also contain the same two catalytic sites, a peroxidase and a COX site, use the same substrate, AA, and form the same product. The detailed structures of the active COX sites in the isoforms are almost identical. Nevertheless, there are very important biological differences between COX-1 and COX-2. The latter is a highly inducible protein, absent from most tissues in normal conditions but increasing rapidly in response to inflammatory stimuli such as bacterial endotoxin, cytokines, or growth factors. Furthermore, there are differences in substrate binding and, particularly, in inhibitor binding sites that allow the isoforms to be inhibited differentially. This difference is therapeutically significant and selective inhibitors of COX-2 exhibit antiinflammatory potency without the gastric and renal toxicities of the aspirin-like drugs. Selective COX-2 inhibitors may also have important effects on cell growth, development, or survival, reflecting the location of COX-2 on the nuclear membrane of cells. Although much is known of the structure of the isoforms, all the questions have not yet been answered. The new therapeutic possibilities offered by selective inhibitors of COX-2 will encourage a continuing and more detailed analysis of the structures and functions of these closely related proteins.
Authors:
Y S Bakhle
Related Documents :
14677369 - Synthesis and docking studies of alkylene-linked dimers of (-)-huperzine a.
19689389 - The structure-ache inhibitory activity relationships study in a series of pyridazine an...
12135759 - The enzymatic activity of adam8 and adam9 is not regulated by timps.
16640839 - Acetylcholinesterase inhibitors from stephania venosa tuber.
16720379 - Matrix metalloproteinase dependent and independent collagen degradation.
15713379 - N-i-propoxy-n-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibi...
11092869 - Sensitive genetic screen for protease activity based on a cyclic amp signaling cascade ...
25485739 - Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributiv...
21595439 - Mechanistic studies of reactions of peroxodiiron(iii) intermediates in t201 variants of...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  35     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:    1999 Apr-May
Date Detail:
Created Date:  2003-09-15     Completed Date:  2003-12-10     Revised Date:  2006-10-26    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  237-50     Citation Subset:  -    
Affiliation:
Department of Applied Pharmacology, National Heart and Lung Institute, Imperial College School of Medicine, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nonsteroidal antiinflammatory agents.
Next Document:  Measurement of differential inhibition of COX-1 and COX-2 and the pharmacology of selective inhibito...